Nauset Wealth Management’s iShares Biotechnology ETF IBB Stock Holding History

Nauset Wealth Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$1K	Buy	+10	New	+$1.3K	﹤0.01%	215

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Nauset Wealth Management's IBB Position: Q1 2022 in Review

Nauset Wealth Management opened a new position in iShares Biotechnology ETF (IBB) in Q1 2022: 10 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #215 among its holdings.

897 funds tracked by Wall St. Rank hold IBB as of Q1 2022.

Nauset Wealth Management held 10 shares of iShares Biotechnology ETF worth $1K as of Q1 2022.
iShares Biotechnology ETF was a new Nauset Wealth Management position in Q1 2022.
iShares Biotechnology ETF made up ﹤0.01% of Nauset Wealth Management's portfolio in Q1 2022, its #215 holding.
897 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2022.

Based on Nauset Wealth Management's 13F filing for Q1 2022, filed 28 Apr 2022.